This adjuvant system combined with the HPV-16 E7 peptide (E7+ND-MPLA/CpG) elicited stronger E7-specific CD8+ T-cell responses in tumor-bearing mice than soluble E7+MPLA/CpG. Here, CD8A is linked to neoplasm.